{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014270","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.443166+00:00","generated_at":"2026-06-11T21:35:35.735637+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MaxCyte Q2 revenue down 6% YoY, core revenue down 14%; expects 2023 core revenue flat to 2022","bullets":["Total revenue $9.0M in Q2 2023 (-6% YoY); core business revenue $8.3M (-14% YoY).","Net loss $10.5M in Q2 vs $8.3M loss in Q2 2022; EBITDA loss $12.0M vs $8.2M.","FY2023 guidance: core revenue now expected comparable to 2022 (flat); SPL program revenue unchanged ~$6M.","Five SPL partnerships signed YTD including Lyell, ViTToria, Prime Medicine; total SPLs at 23.","Cash and investments $216.1M as of June 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014270","json":"https://secwatch.observer/filing/0001558370-23-014270.json","markdown":"https://secwatch.observer/filing/0001558370-23-014270.md","text":"https://secwatch.observer/filing/0001558370-23-014270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/0001558370-23-014270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/mxct-20230809x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:35:35.735637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df0ef9c6aa6aa79dfdaaeaadebb21aa87cb5e313","claim":"MAXCYTE, INC. reported the quarter ended June 30, 2023 results: revenue $9.0 million, net income $10.5 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue for the second quarter of 2023 was $9.0 million, compared to $9.6 million in the second quarter of 2022, representing a decline of 6%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/0001558370-23-014270-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$9.0 million"},{"label":"Net income","value":"$10.5 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f96809dbf7be03932ad5ef8b1ae6664f27d09b5c","claim":"MAXCYTE, INC. reported the six months ended June 30, 2023 results: revenue $17.6 million, net income $21.4 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue for the first half of 2023 was $17.6 million, compared to $21.2 million in the first half of 2022, representing a decline of 17%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/0001558370-23-014270-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"$17.6 million"},{"label":"Net income","value":"$21.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}